Rigel Pharmaceuticals, Inc. RIGL NASDAQ · Healthcare · United States
$42.53 -0.91% -$0.39
Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 107 USD is left as net profit.
- Revenue grew by 35% a year over the last 3 years.
- It earns 68 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $46.6M against $7.79M.
What to watch
- Its last loss-making year was 3 years ago.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 2.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 35% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 10 USD
- Research and development 19 USD
- Sales and administration 44 USD
- Taxes and other -80 USD
- Net profit 107 USD
Net profit, industry median (Biotechnology) -10 USD
Out of every 100 USD of revenue, 107 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 7
- Sell 0
Today's price within the analysts' price targets
The average target of $67 is 58% above today's price. 53% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 79%
- Contract revenues from collaborations 21%
- Government Contract 0.1%
By region
The company reports no revenue by region.
Product brings in 79% of revenue.
Segments in detail